Loading...
XHKG
6622
Market cap221mUSD
Dec 05, Last price  
3.15HKD
1D
0.64%
1Q
-18.81%
IPO
-74.80%
Name

Zhaoke Ophthalmology Ltd

Chart & Performance

D1W1MN
XHKG:6622 chart
P/E
P/S
22.54
EPS
Div Yield, %
Shrs. gr., 5y
0.41%
Rev. gr., 5y
%
Revenues
69m
+269.73%
0000018,750,00069,324,000
Net income
-237m
L-38.32%
-36,881,000-123,660,000-728,636,000-2,134,215,000-410,459,000-385,038,000-237,493,000
CFO
-254m
L-21.61%
22,082,000-55,212,000-103,425,000-245,143,000-331,050,000-323,664,000-253,723,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, and commercialization of therapies that address unmet medical needs in the People's Republic of China. It is developing various drugs that cover ophthalmic indications affecting the anterior and posterior segments, including dry eye diseases, wet age-related macular degeneration, diabetic macular edema, myopia, and glaucoma. The company was formerly known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited was incorporated in 2017 and is headquartered in Guangzhou, the People's Republic of China.
IPO date
Apr 29, 2021
Employees
321
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT